HBV-HIV Coinfection Research Network

Completed

Conditions studied: Hepatitis B, Human Immunodeficiency Virus

In brief

Despite effective ART that can suppress both HIV and HBV, HBV-related liver disease remains a significant co-morbidity in this population. Little is known about the histologic spectrum of liver disease, the significance of complete vs. incomplete HBV suppression, the utility of novel virologic and serum markers of disease severity, and the long-term renal and bone effects of TDF-based therapy. This proposal will address these important questions and impact the science and health of those coinfected with HBV-HIV.

Key facts

Study ID

NCT01924455

Run by

Virginia Commonwealth University

People needed

139

Starts

2014-04-01

Expected to finish

2019-03-31

Last updated by the study team

2023-05-16

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California — San Francisco, California, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• NIDDK — Bethesda, Maryland, United States
• Mass General Hospital — Boston, Massachusetts, United States
• Washington University — St Louis, Missouri, United States
• UT Southwestern — Dallas, Texas, United States
• Virginia Commonwealth University — Richmond, Virginia, United States
• Toronto Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.